Why the study?
There is currently no specific treatment for improving diastolic function in hypertrophic cardiomyopathy, prompting investigation into whether myeloperoxidase provides a novel therapeutic target.
Does MPO inhibition with AZD5904 improve relaxation defects in hypertrophic cardiomyocytes?
Does MPO inhibition with AZD5904 improve relaxation defects in hypertrophic cardiomyocytes?
MPO inhibition alleviates relaxation defects in hypertrophic cardiomyocytes, highlighting a potential novel therapeutic target for diastolic dysfunction in HCM.
No takes yet. Share an insight, caveat, or question.
May offer new target for HCM diastolic dysfunction; leaves open whether MPO inhibition improves symptoms.
Ramachandra et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: